Chen Gengfu
Chen Gengfu is a well-known expert in difficult diseases and special medicines of traditional Chinese medicine in China, the director of Shijiazhuang Huikang Traditional Chinese Medicine Hospital, and an expert in the treatment of blood diseases. He has made extraordinary achievements in the treatment of blood diseases, holds multiple patents, and has many years of clinical practice experience, which has cultivated his eclectic way of thinking and his ability to be good at comprehensive evaluation across disciplines. Coupled with his "natural preference for Chinese medicine and endless curiosity", he has not only read ancient medical monographs, but also studied modern medicine, hoping to spend his whole life to find the essence of the motherland's medicine. He firmly believes that it is completely promising to completely cure difficult diseases like blood diseases based on traditional Chinese medicine.
Chinese name: Chen Gengfu
Nationality: Chinese
Occupation: Doctor
Main achievements: "Gold Award for Invention Patent Technology"
Representative work: "Five Source Balanced Immunotherapy"
Gender: Male
Position: Dean of Shijiazhuang Huikang Traditional Chinese Medicine Hospital, etc.
Achievements and Honors
Over the years, Professor Chen has published 28 academic papers and 3 medical monographs in authoritative publications at home and abroad, especially his research results on blood diseases "Five Source Balanced Immunotherapy" and "Clinical" "Four Parts Treatment Principle" is considered to have "created a new perspective on studying blood diseases and their treatment approaches from the blood production process chain", which has attracted widespread attention in the medical community. The series of pure Chinese medicine formulas and treatment technologies it developed have also been awarded national inventions. Patent and "Invention Patent Technology Gold Medal". In recognition of his outstanding contribution to medicine, in 1999 he was admitted as a life member by the International Association for the Promotion of Traditional Medicine and Health Care. In 2002, he was awarded the "Outstanding Contribution Award for Promoting Chinese Traditional Medicine Culture" at the Second National Traditional Medicine Exchange Conference.
Character expertise
Chen Gengfu: My view on blood production in aplastic anemia
Although the pathological characteristics of blood diseases such as aplastic anemia are in the bone marrow, their pathogenesis runs through to the entire blood chain. This is the latest view of Professor Chen Gengfu, a famous expert on hematology, an expert on special traditional Chinese medicine and director of Shijiazhuang Huikang Hospital of Traditional Chinese Medicine, on blood diseases such as aplastic anemia. He combined traditional Chinese medicine meridian science, Zangxiang science, the theory of qi, blood, body fluid and blood with modern biological cytology to create the "Five Source Balanced Immunotherapy", which is considered to be the first general method of traditional Chinese medicine to treat blood diseases. It also creates a novel way to treat hematologic diseases from the perspective of optimizing and rebuilding the blood production chain (raw material supply, hematopoietic environment, and hematopoietic mechanism).
The combination plan of "1 3 Clinical Four Parts Treatment Principles" proposed by him provides a good reference for the research on the treatment model of blood diseases by integrating traditional Chinese and Western medicine. His "Reunderstanding of blood diseases from the perspective of the blood production chain and optimizing the treatment combination model" and "The leading significance of five-source balanced immunotherapy in the treatment of blood diseases such as aplastic anemia" have attracted widespread attention. "Four Parts of Treatment"--Special Therapy for the Treatment of Leukemia
Leukemia has become a common and frequently-occurring disease, seriously endangering human health and life. After more than ten years of hard work, the Leukemia Research Group of the Hematology Prevention and Treatment Center of Huikang Hospital, under the guidance of the "active plant myeloablative method", explored and innovated based on the disease and pathological characteristics of leukemia and its evolution rules, and concluded that The clinically effective leukemia needle treatment method - "Four Parts Treatment Principle" has been clinically promoted for five years, and tens of thousands of leukemia patients have been cured, creating a new miracle in the history of leukemia treatment.
The hematology research team of Huikang Hospital believes that the disease belongs to the category of "marrow poisoning" and "deficiency tuberculosis". Leukemia is caused by heat stagnation in the bone marrow from the inside out, and its pathological changes include heat knots, blood consumption, The coexistence of blood circulation and stasis, involving five levels of marrow, blood, nutrient, qi and health, makes the condition complex. Its basic pathogenesis lies in the accumulation of evil toxins and the loss of kidney essence.
In addition to leukemia being related to environmental pollution, chemical drugs and exposure to radioactive substances, scientific researchers have found that the occurrence of leukemia is also related to the endogenous pathogenic GYA factor in cells and the exogenous GYB outside cells. Factors related, endogenous pathogenic GYA factors destroy the stability of the bone marrow internal environment, increase bone marrow pressure, and the sinusoidal barrier may be ruptured, allowing immature cells at various stages to enter the blood, resulting in increased activity of immature cells and stagnant development; exogenous GYB pathogenic factors cooperate with leukemia cells to mainly damage the liver, spleen, kidney and other organs.
The research team of the Leukemia Department of Huikang Hospital uses original active botanical medicine. Its main active ingredient "active myeloablative factor" enters the body and accumulates in the patient's hematopoietic tissue to remove toxins and foreign matter, causing Leukemia cell apoptosis; specifically binds to endogenous GYA factors, antagonizes their pathogenicity, and inhibits the metastasis of blood disease cells and further damage to internal organs. Through "purification", "detoxification", "replenishment" and "conditioning", the hematopoietic microenvironment is improved.
Through the above-mentioned effects, "active myeloablative factors" carry out multi-level and multi-target specific treatment of diseased tissues and organs (bone marrow, liver, spleen, kidneys, lymph nodes, etc.), thoroughly removing and purifying all types of diseases. The hematopoietic microenvironment of tissues and organs improves the hematopoietic "soil" and inhibits the division, reproduction, transfer and infiltration of leukemia cells, so that all hematopoietic tissues and organs, especially the main hematopoietic organ - bone marrow, can be "purified" and "baptized", and the hematopoietic function can be carried out Recover and achieve the "effect of easy blood and marrow replacement method". At this time, the patient's peripheral blood rod-shaped nuclei began to rise, fatigue, low-grade fever, oral ulcers, etc. gradually improved, and bone pain gradually eased. In specific application, the treatment should be conducted in different levels and stages according to the individual differences of the patients, the severity of the condition, the internal and external conditions of the pathogenesis, and then the ideal therapeutic effect can be obtained. The difference between five-source balanced immunotherapy and traditional therapy
Compared with traditional therapy, five-source balanced immunotherapy is no longer limited to the bone marrow that directly performs hematopoietic function. It also goes beyond the traditional treatment of kidney and spleen in traditional Chinese medicine. Traditionally, the hematopoietic process is regarded as a complete chain consisting of hematopoietic raw materials, hematopoietic environment, and hematopoietic mechanism. The optimization of the extra-marrow supply mechanism of hematopoietic raw materials is included in the treatment plan, which is a pioneering work. In addition, for the activation of bone marrow hematopoietic function, a roundabout induction method was pioneered, which indirectly activates bone marrow hematopoietic function by activating relevant induction factors. In addition, the method of removing toxins from the body does not involve fighting poison with poison, nor does it rely on the properties of strengthening and removing toxins to guide the toxins and give them a way out. Professor Chen also used his experience in drug use in neurology and orthopedic disease treatment to make the drug's permeability and activity level even better, allowing the drug to quickly reach the bone marrow and activate the nerve center.